Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05612867 · ClinicalTrials.gov registry record
Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C
A clinical trial, sponsored by Arrowhead Regional Medical Center.
- Completed
- Registry status
- 54
- Enrollment target
NCT05612867: Completed study, sponsored by Arrowhead Regional Medical Center.
NCT05612867 is a clinical trial that has completed, run by Arrowhead Regional Medical Center. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05612867 has completed, sponsored by Arrowhead Regional Medical Center.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
Burn injury is marked by a large release of inflammatory mediators which disrupt the normal capillary barrier and cause a rapid shift of intravascular fluid into interstitial spaces, ultimately leading to shock and death. As such, adequate fluid management and resuscitation is critical for burn patients to prevent further cellular injury. Technologies and medical options such as cardiac output monitoring along with early tube feeding and vitamin C administration have developed slowly over the years. Effective management of the Systemic Inflammatory Response Syndrome response and metabolic derangement is crucial for the survival of burn patients. In particular, vitamin C administration has shown to significantly decreases early post-burn lipid peroxidation, reduce microvascular leak of fluid by preventing endothelial dysfunction, and decreases edema formation in burned tissue. Vitamin C is a cheap and widely available antioxidant which has been shown to significantly effective in positively impacting clinical outcomes in burn resuscitation. We aim to evaluate the efficacy of vitamin C in burns greater than 20% total body surface area on clinical outcomes such as length of hospital stay, total fluid requirements, and mortality.
Primary Outcome
Survival within the first 28 days
Interventions
- DIETARY_SUPPLEMENT Vitamin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-12-12 |
| Est. Completion | 2021-01-08 |
What the finished NCT05612867 record still lists
NCT05612867 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Vitamin C is the first listed.
NCT05612867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05612867 about?
NCT05612867 is a clinical study titled "Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C". Burn injury is marked by a large release of inflammatory mediators which disrupt the normal capillary barrier and cause a rapid shift of intravascular fluid into interstitial spaces, ultimately leading to shock and death. As such, adequate fluid management and resuscitation is critical for burn pati...
What is the current status of trial NCT05612867?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2020-12-12. Estimated completion is 2021-01-08.
What interventions are being tested in trial NCT05612867?
The interventions under investigation include: Vitamin C (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05612867?
This trial is sponsored by Arrowhead Regional Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI